(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 254.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Precigen's revenue in 2025 is $3,925,000.On average, 1 Wall Street analysts forecast PGEN's revenue for 2025 to be $2,293,535,189, with the lowest PGEN revenue forecast at $2,293,535,189, and the highest PGEN revenue forecast at $2,293,535,189. On average, 2 Wall Street analysts forecast PGEN's revenue for 2026 to be $16,113,554,920, with the lowest PGEN revenue forecast at $4,860,530,344, and the highest PGEN revenue forecast at $27,366,579,497.
In 2027, PGEN is forecast to generate $58,835,058,468 in revenue, with the lowest revenue forecast at $58,835,058,468 and the highest revenue forecast at $58,835,058,468.